Why the study?
Does lercanidipine reduce blood pressure safely in patients with hypertension?
Does lercanidipine reduce blood pressure safely in patients with hypertension?
Lercanidipine is an effective and well-tolerated third-generation calcium antagonist for the treatment of hypertension, including in patients with comorbidities.
Supports lercanidipine consideration for hypertension without HR effects; leaves open prospective RCT confirmation.
The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity.
No takes yet. Share an insight, caveat, or question.
Shehyan et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: